Picrasma Anti-Dysentery Capsules 200mg

Picrasma Anti-Dysentery Capsules 200mg: What the Published Guidance Says

Systemic antifungals, antivirals and anthelmintics supplied with full batch documentation — including fluconazole at the injection concentration of 2 mg/mL carried on the WHO Model List, and albendazole as a listed intestinal anthelmintic.

Buyers usually settle three things before ordering Picrasma Anti-Dysentery Capsules 200mg: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.

• Fluconazole is carried on the Model List in both oral and intravenous form The 24th WHO Model List (2025) lists fluconazole as a 50 mg capsule, an injection of 2 mg/mL in vial, an oral liquid of 50 mg/5 mL and a powder for oral liquid of 50 mg/5 mL, classified under antifungal medicines. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
• Albendazole is listed as an intestinal anthelmintic Albendazole appears on the Model List among intestinal anthelmintics, a class that also includes ivermectin, levamisole, mebendazole, niclosamide, praziquantel and pyrantel. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
• Ribavirin's listing is specifically combination-based The Model List carries ribavirin injection for intravenous administration and solid oral dosage forms, with the note that for hepatitis C it is used in combination with direct-acting antiviral medicines. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)

Each point above is reproduced because it has a practical consequence for Picrasma Anti-Dysentery Capsules 200mg: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.

Testing, Monographs & Batch Documentation

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Release testing for Picrasma Anti-Dysentery Capsules 200mg follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

The batch record for this product normally includes:

• Testing for assay of the active substance
• Testing for related substances and impurities
• Testing for dissolution or release profile (solid oral forms)
• Testing for uniformity of dosage units
• Testing for water content and pH where applicable
• Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

Pack Configuration, Artwork & Shipping Documents

• Pack size: 12 capsules/blister*2/box. Non-standard pack sizes can be quoted against your artwork.
• Shelf life: 36months. Stability data for the marketed pack is included in the dossier.
• Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
• Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.

Dossier, Authority Filings & Tender Documentation

The legal manufacturer named on every document for Picrasma Anti-Dysentery Capsules 200mg is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.

• Site Master File and GMP certificate for the manufacturing workshops.
• Method validation, stability protocol and the shelf-life justification for the marketed pack.
• Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
• Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
• Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.

Picrasma Anti-Dysentery Capsules 200mg is presented here against antifungal, antiviral and anthelmintic medicines named in the WHO Model List. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.

Other Antifungals & Antivirals Products in This Range

• Amantadine 100mg Capsules — 100mg
• Ribavirin Injection 100mg — 100mg
• Albendazole 200mg Tablets — 200mg
• Fluconazole Injection 200mg/100mL — 200mg/100mL

Browse the full Antifungals & Antivirals range; all Capsules; the complete product catalogue.